<DOC>
	<DOC>NCT01529424</DOC>
	<brief_summary>The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS ApoC-III Rx vs. Placebo on fasting total apoC-III levels.</brief_summary>
	<brief_title>Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Severe hypertriglyceridemia HbA1c &gt;/=9.0%, type 1 diabetes, or history of outpatient insulin use for more than 2 weeks in the last year Body mass index (BMI) &gt;40 kg/m2 History of bariatric surgery or currently on weight loss drugs Use of oral contraceptives or hormone replacement therapy or statins unless stable for 3 months prior to dosing Group 1 and 2 patients: Use of systemic corticosteroids, fibrates, niacin, fish oil or other products containing omega3 fatty acids within 6 weeks of dosing. Group 3 patients: unable to discontinue use of systemic corticosteroids at least 6 weeks prior to dosing ; use of niacin, fish oil, or other products containing omega3 fatty acids unless on a stable well controlled dose for at least 30 days prior to screening that is not anticipated to change during the study period. Group 4 patients: unable to discontinue use of systemic corticosteroids at least 6 weeks prior to dosing; use of fibrates niacin, fish oil, or other products containing omega3 fatty acids unless on a stable well controlled dose for at least 30 days prior to screening that is not anticipated to change during the study period. Use of topical corticosteroids, anticoagulants, or drugs or dietary supplements with potential lipidaltering effects unless dose is stable and well controlled for 30 days prior to dosing Any Screening laboratory values that are out of allowed reference ranges Inability to comply with protocol or study procedures Any other significant illness or condition that may adversely affect the subjects participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hypertriglyceridemia</keyword>
</DOC>